KKR prices secondary offering of 5 million BridgeBio shares

KKR Genetic Disorder L.P. priced a secondary offering of 5,000,000 shares of BridgeBio Pharma, Inc. (Nasdaq: BBIO) common stock, according to a press release from the company.

BridgeBio will not sell any shares in the transaction and will not receive any proceeds from the offering. The offering is expected to close on Aug. 17, 2026, subject to customary closing conditions.

William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC are acting as joint book-running managers for the offering.

The shares are being offered under an automatic shelf registration statement on Form S-3ASR filed with the Securities and Exchange Commission, which became effective upon filing on July 24, 2026.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• QNB Corp. overallotment option adds 160,714 shares at $42 each
• Aveanna selling stockholders launch 15M share secondary offering